Sino Biopharmaceutical

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

In what Merck describes as “early signs of promising anti-tumor activity,” the PD-1xVEGF bispecific, coded MK-2010, induced an unconfirmed ORR of 55%.

Angus Liu Apr 17, 2026 3:00pm

Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

Robot Holding Shopping Cart With Cardboard Boxes

AI-driven Formation snaps up oral autoimmune asset in $500M play

Jan 29, 2026 1:20pm

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova

Jul 15, 2025 10:16am

F-star breaks free from invoX after $161M acquisition

Apr 4, 2025 10:03am

Photo of three hands placing together three white puzzle pieces

Takeda adds F-Star collab to constellation worth up to $1B

Jul 5, 2023 2:00pm